Pre-earnings options volume in Cidara Therapeutics is 3.2x normal with calls leading puts :. Implied volatility suggests the market is anticipating a move near 20.0%, or 34c, after results are released. Median move over the past eight quarters is 2.5%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on CDTX:
- Cidara Therapeutics Announces Pricing of Public Offerings of Common Stock and Preferred Stock
- Cidara Therapeutics 11.8M share Spot Secondary priced at $1.40
- Cidara Therapeutics Announces Underwritten Public Offerings of Common Stock and Preferred Stock
- Cidara Therapeutics announces common stock, preferred stock offerings
- Cidara Therapeutics announces interim Phase 2a data of CD388